• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

超声造影在鉴别肝细胞癌和胆管细胞癌中的应用。

Contrast-enhanced ultrasound (CEUS) for differentiating between hepatocellular and cholangiocellular carcinoma.

出版信息

Ultraschall Med. 2012 Dec;33(7):E191-E195. doi: 10.1055/s-0031-1282029. Epub 2011 Dec 22.

DOI:10.1055/s-0031-1282029
PMID:22194045
Abstract

PURPOSE

HCC and CC are the most common primary malignancies of the liver. There is only minimal evidence as to whether these two entities can be reliably differentiated by contrast-enhanced ultrasound.

MATERIALS AND METHODS

We retrospectively analyzed the CEUS pattern of 39 patients with HCC, 11 patients with intrahepatic cholangiocarcinoma (ICC), 3 patients with Klatskin tumor, and 4 patients with gallbladder carcinoma. CEUS was performed using a standardized protocol (low MI, SonoVue®) with documentation of the arterial, portal-venous, and late phase. Besides the contrast enhancement compared to the adjacent normal liver tissue in every phase, the specific contrast pattern during the arterial phase (complete filling, incomplete filling of different grade, rim sign) was analyzed.

RESULTS

Most HCC and ICC showed hyperenhancement during the arterial phase, with hypoenhancement or isoenhancement in the portal-venous and late phase. Hyperenhancement during the portal-venous phase was only observed in some cases of HCC, but not in ICC. In the case of arterial hyperenhancement, HCC showed complete filling more often than ICC. In the case of incomplete filling, the area of contrast-enhanced tumor in most HCCs was larger than in ICCs. A rim sign was present in only less than half ICCs, but in no HCCs.

CONCLUSION

HCC and ICC differ to some extent in their CEUS enhancement pattern. Incomplete arterial hyperenhancement is more often seen in ICC than in HCC. A rim sign seems to be specific for ICC, but is only rarely present. However, in a case-to-case decision, due to overlapping characteristics, a reliable differentiation between the two tumor types by CEUS alone is very often not possible.

摘要

目的

肝癌和胆管细胞癌(CC)是肝脏最常见的原发性恶性肿瘤。关于这两种肿瘤是否可以通过增强超声可靠地区分,仅有少量证据。

材料和方法

我们回顾性分析了 39 例 HCC、11 例肝内胆管细胞癌(ICC)、3 例 Klatskin 肿瘤和 4 例胆囊癌患者的超声造影(CEUS)模式。CEUS 采用标准化方案(低机械指数,声诺维®)进行,记录动脉期、门静脉期和晚期的资料。除了在每个阶段与相邻正常肝组织的对比增强外,还分析了动脉期的特定对比模式(完全填充、不同程度的不完全填充、边缘征)。

结果

大多数 HCC 和 ICC 在动脉期表现为高增强,门静脉期和晚期表现为低增强或等增强。在 HCC 中仅观察到部分病例在门静脉期出现高增强,而在 ICC 中则没有。在动脉期高增强的情况下,HCC 比 ICC 更常表现为完全填充。在不完全填充的情况下,大多数 HCC 中增强肿瘤的面积大于 ICC。边缘征仅见于不到一半的 ICC 中,而在 HCC 中则没有。

结论

HCC 和 ICC 在 CEUS 增强模式上存在一定差异。在 ICC 中,不完全动脉期高增强比 HCC 更常见。边缘征似乎是 ICC 的特异性表现,但很少见。然而,在具体病例中,由于特征重叠,仅凭 CEUS 很难可靠地区分这两种肿瘤类型。

相似文献

1
Contrast-enhanced ultrasound (CEUS) for differentiating between hepatocellular and cholangiocellular carcinoma.超声造影在鉴别肝细胞癌和胆管细胞癌中的应用。
Ultraschall Med. 2012 Dec;33(7):E191-E195. doi: 10.1055/s-0031-1282029. Epub 2011 Dec 22.
2
LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.肝脏影像报告和数据系统-超声造影 - 关于高危人群肝细胞癌诊断的超声造影算法提案
Ultraschall Med. 2016 Dec;37(6):627-634. doi: 10.1055/s-0042-112221. Epub 2016 Aug 3.
3
CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial.320例肝细胞癌和肝内胆管细胞癌患者的对比增强超声检查——早期或晚期洗脱的重要性:DEGUM多中心试验的亚分析
Ultraschall Med. 2015 Apr;36(2):132-9. doi: 10.1055/s-0034-1399147. Epub 2015 Mar 26.
4
Characteristics of contrast-enhanced ultrasound in distinguishing small (≤3 cm) hepatocellular carcinoma from intrahepatic cholangiocarcinoma.超声造影在鉴别小(≤3厘米)肝细胞癌与肝内胆管癌中的特征
Medicine (Baltimore). 2018 Oct;97(41):e12781. doi: 10.1097/MD.0000000000012781.
5
Dynamic contrast-enhanced ultrasound (DCE-US) for the characterization of hepatocellular carcinoma and cholangiocellular carcinoma.动态对比增强超声(DCE-US)用于肝细胞癌和胆管细胞癌的特征描述。
Ultraschall Med. 2014 Dec;35(6):522-7. doi: 10.1055/s-0034-1385170. Epub 2014 Sep 9.
6
Applications of Dynamic Contrast-Enhanced Ultrasound in Differential Diagnosis of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma in Non-cirrhotic Liver.动态对比增强超声在非肝硬化肝脏肝细胞癌和肝内胆管细胞癌鉴别诊断中的应用。
Ultrasound Med Biol. 2023 Aug;49(8):1780-1788. doi: 10.1016/j.ultrasmedbio.2023.03.026. Epub 2023 May 6.
7
Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?增强超声能区分肝内胆管细胞癌和肝细胞癌吗?
World J Gastroenterol. 2020 Jul 21;26(27):3938-3951. doi: 10.3748/wjg.v26.i27.3938.
8
Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound.高危患者肝内胆管细胞癌与肝细胞癌的鉴别诊断:应用超声造影的预测模型。
World J Gastroenterol. 2018 Sep 7;24(33):3786-3798. doi: 10.3748/wjg.v24.i33.3786.
9
Detailed analysis of temporal features on contrast enhanced ultrasound may help differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis.对比增强超声对时间特征的详细分析可能有助于鉴别肝硬化患者肝内胆管癌与肝细胞癌。
PLoS One. 2014 May 29;9(5):e98612. doi: 10.1371/journal.pone.0098612. eCollection 2014.
10
Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017.在有和无风险因素的患者中鉴别肝内胆管细胞癌和肝细胞癌:对比增强超声肝脏成像报告和数据系统 2017 版 LR-M 标准的评估。
Eur Radiol. 2020 Jan;30(1):461-470. doi: 10.1007/s00330-019-06317-2. Epub 2019 Jul 11.

引用本文的文献

1
Unraveling distinctions between contrast-enhanced ultrasound and CT/MRI for liver mass diagnosis.解析超声造影与CT/MRI在肝脏肿块诊断中的差异
Ultrasonography. 2025 Jan;44(1):19-30. doi: 10.14366/usg.24163. Epub 2024 Oct 16.
2
Management Consensus Guidelines for Hepatocellular Carcinoma: 2023 Update on Surveillance, Diagnosis, Systemic Treatment, and Posttreatment Monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan.肝细胞癌管理共识指南:台湾肝癌协会和台湾胃肠病学会2023年关于监测、诊断、全身治疗及治疗后监测的更新
Liver Cancer. 2024 Feb 12;13(5):468-486. doi: 10.1159/000537686. eCollection 2024 Oct.
3
Diagnostic Value of CEUS LI-RADS Version 2017 in Differentiating AFP-Negative Hepatocellular Carcinoma from Other Primary Malignancies of the Liver.
2017版CEUS LI-RADS在鉴别甲胎蛋白阴性肝细胞癌与肝脏其他原发性恶性肿瘤中的诊断价值
Diagnostics (Basel). 2021 Dec 1;11(12):2250. doi: 10.3390/diagnostics11122250.
4
Sarcomatoid hepatocellular carcinoma mimicking hepatic abscess: A case report.酷似肝脓肿的肉瘤样肝细胞癌:一例报告。
Medicine (Baltimore). 2020 Sep 25;99(39):e22489. doi: 10.1097/MD.0000000000022489.
5
Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?增强超声能区分肝内胆管细胞癌和肝细胞癌吗?
World J Gastroenterol. 2020 Jul 21;26(27):3938-3951. doi: 10.3748/wjg.v26.i27.3938.
6
Diagnosis efficacy of CEUS for hepatic inflammatory lesions.CEUS 对肝脏炎性病变的诊断效能。
J Clin Lab Anal. 2020 Jun;34(6):e23231. doi: 10.1002/jcla.23231. Epub 2020 Feb 3.
7
Contrast-enhanced Ultrasound Features of Intrahepatic Cholangiocarcinoma: A New Perspective.肝内胆管癌的超声造影特征:新视角。
Sci Rep. 2019 Dec 18;9(1):19363. doi: 10.1038/s41598-019-55857-6.
8
The Role of US Contrast Agents in US-Guided Biopsy of Focal Liver Lesions: A Pictorial Review.超声造影剂在超声引导下肝脏局灶性病变活检中的作用:图文综述
Ultrasound Int Open. 2019 Jan;5(1):E11-E19. doi: 10.1055/a-0770-4237. Epub 2018 Nov 23.
9
Comparison between M-score and LR-M in the reporting system of contrast-enhanced ultrasound LI-RADS.M 评分与 LR-M 在对比增强超声 LI-RADS 报告系统中的比较。
Eur Radiol. 2019 Aug;29(8):4249-4257. doi: 10.1007/s00330-018-5927-8. Epub 2018 Dec 19.
10
Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound.高危患者肝内胆管细胞癌与肝细胞癌的鉴别诊断:应用超声造影的预测模型。
World J Gastroenterol. 2018 Sep 7;24(33):3786-3798. doi: 10.3748/wjg.v24.i33.3786.